- ADVERTISEMENT
-
Most Popular
- ADVERTISEMENT
RHHBY
Add Roche to Your List of Ebola Stocks, But …
Ebola stocks have doled out some big gains to savvy traders this year, but investors looking for Roche (RHHBY) to do the same may want to rethink their expectations.
Gilead Stock Will Rise on Sovaldi® Sales
Gilead's breakthrough Hepatitis C drug, Sovaldi®, will drive revenue and profits for the rest of 2014 and into 2015.
Roche Proves You Can’t Judge a Book by Its Cover
Roche stock may not be an NYSE or NASDAQ-listed equity, but when you look at the details, RHHBY is plenty investment-worthy.
3 Huge Healthcare Trends Can Fatten Your Portfolio
Healthcare concerns in the U.S. are being addressed by companies in the industry. These 3 issues can lead investors to stock opportunities
Our Stock Earnings Rundown – HSY KMB DFS SHW LUV TMO AMGN
A big week for earnings and dividend increases includes these 8 stocks in our portfolio.
Roche’s Breast Cancer Drug Approval Is Just the Beginning
It might have been dismissed as irrelevant by most investors, but Roche and its Perjeta could reshape the breast cancer drug landscape.
Study: New Bird Flu Resistant to Roche’s Tamiflu
Physicians in China have noted that some patients with bird flu are not responding to treatment with Tamiflu, the only known drug used to fight the infection.
India Drops Patent Bomb on Novartis
India's ruling on a Novartis patent draws a clear line of favor between generic drug companies and Big Pharma.
Biotech Movers: Keryx Jumps, Sarepta Slips
Among last week's highlights, Keryx jumps on a solid Phase III trial, Sarepta gets pounded from a fake tweet and Halozyme suffers from analyst downgrades.
Flu Season: Where Investors Can Find Relief
This year's flu looks particularly troublesome, but that's good new for the many companies that benefit from flu sufferers' ills. Here's a look at some of them.
Biotech Movers: A Tough Week All Around
Amarin Corp. slides on dashed buyout hopes, while Sarepta, Galena and others also faced serious setbacks.
Who Has the Best Pharma Pipeline?
A look through Big Pharma's drug pipelines shows a lot of promise across several companies, but one firm stands out as having big-time revenue growth potential.
Israel: Beyond the Risk, Opportunities Beckon
When you think of Israel, you probably think of conflict. But it has a strong economy and growing companies if you're willing to be a bit daring.
Pharma’s Q2 Earnings Lesson: The Big Picture Looks Good
The promising signs coming out of pharma this quarter doesn't mean you can just pick a stock out of a hat -- but it does mean a few are worth picking.
Novartis Wins Approval for Breast Cancer Drug
The FDA has granted approval for Novartis' drug Afinitor to be used as a treatment for breast cancer after it showed promise in clinical trials.
Medidata Solutions a Strong Buy in Cloud Computing
Medidata Solutions is a fast-growing cloud services provider to the health care industry that is poised for even better growth and is a buying opportunity
Nestle: A Global Dividend Powerhouse
Nestle is a world wide brand name that produces products, earnings, and dividends at a remarkable rate every year. Nestle is a great portfolio buy.
